Filing Flows › Puma Biotechnology (PBYI) › Q3 2026 › vs Q2 2026
Puma Biotechnology (PBYI) Q3 2026 vs Q2 2026 (quarter over quarter)
Puma Biotechnology's revenue fell $1.4M (-2%) from $56.5M in Q2 2026 to $55.1M in Q3 2026. Operating margin 9.6% against 13.4% (-3.8 pts).
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 9.6% | 13.4% | -3.8 pts |
| Net margin | 10.9% | 14.5% | -3.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $55.1M | $56.5M | −$1.4M | -2% |
| Other income, net | $900K | $660K | $240K | +36% |
| Operating profit | $5.3M | $7.6M | −$2.3M | -30% |
| Costs & expenses | $49.8M | $48.9M | $883K | +2% |
| Pre-tax earnings | $6.2M | $8.2M | −$2.0M | -25% |
| Cost of revenue | $15.2M | $12.5M | $2.7M | +22% |
| Research & development | $18.3M | $18.9M | −$595K | -3% |
| SG&A | $16.3M | $17.5M | −$1.2M | -7% |
| Net earnings | $6.0M | $8.2M | −$2.2M | -27% |
| Income tax | $200K | $56K | $144K | +257% |
Questions
How much did Puma Biotechnology's revenue grow quarter over quarter in Q3 2026?
Puma Biotechnology's revenue fell $1.4M (-2%) from $56.5M in Q2 2026 to $55.1M in Q3 2026. Operating margin 9.6% against 13.4% (-3.8 pts).